San Antonio, Texas — November 25, 2025 — Leads & Copy — Exact Sciences Corp. (Nasdaq: EXAS) will present 10 abstracts from its Precision Oncology portfolio at the 2025 San Antonio Breast Cancer Symposium (SABCS) from December 9-12 in San Antonio, Texas.
The data presented will expand upon Exact Sciences’ dedication to innovation, clinical evidence, and equitable breast cancer care, equipping clinicians with solutions for patient needs throughout every cancer care stage.
Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences, said that Oncotype DX has set a global standard as a predictive and prognostic test in breast cancer, which helps clinicians guide therapy decisions and improve outcomes while reducing disparities. He added that the data presented at SABCS reaffirms Exact Sciences’ leadership in breast cancer prediction and prognosis, and expands its evidence base for Oncodetect as a recurrence predictor and tool for personalizing surveillance in high-risk patients.
Data presentations across Exact Sciences’ Precision Oncology portfolio include:
The Oncodetect Test®:
Evaluation of a Whole-Exome Sequencing Tumor-informed Circulating Tumor DNA MRD Assay in Patients with Early Triple-Negative Breast Cancer (TNBC) receiving Neoadjuvant Chemotherapy (NAC) with or without Atezolizumab: A Prospective Sub-study of the NSABP-B59/GBG-96-GeparDouze Trial:
In partnership with the National Surgical Adjuvant Breast and Bowel Project (NSABP), this sub-study evaluated MRD in patients with triple-negative breast cancer (TNBC) and demonstrated the strong predictive performance of the Oncodetect test using prospectively collected samples from a Phase III randomized trial.The session is scheduled for RF4-03, Thursday, December 11, 2025, from 4:30-5:30 PM.
Prospective Breast Cancer Clinical Validation Study of an Ultrasensitive, Tumor Informed, Whole Genome, Circulating Tumor DNA Assay to Detect Molecular Residual Disease and Predict Recurrence of High-Risk Early Breast Cancer Treated with Standard (Neo)adjuvant Therapy; NSABP B-64/EXActDNA-003NCT06401421:
Conducted in collaboration with the NSABP, this large-scale, ongoing trial is enrolling more than 1,800 participants across all breast cancer subtypes. Tracking patients from diagnosis through treatment and post-therapy surveillance, the study will deliver multiple readouts beginning in 2027 that will further expand the clinical evidence supporting the Oncodetect test. The session is scheduled for PS5-08-21, Friday December 12, 2025, from 12:30-2:00 PM.
Early Adoption of Molecular Residual Disease Testing in Breast Cancer Patients using Real World Data:
This real-world data analysis of MRD adoption trends in breast cancer highlights the increasing use and integration of these tests into clinical practice. The session is scheduled for PS2-04-01, Thursday, December 11, 2025, from 5:00-6:30 PM.
The Oncotype DX Breast Recurrence Score® Test:
Clinical and economic impact of the 21-gene assay for guiding treatment in patients with HR+/HER2- early breast cancer across racial and ethnic subgroups in the US:
The study confirms that utilization of the Oncotype DX Breast Recurrence Score test to guide adjuvant therapy decision-making can lead to improved outcomes and reduce costs across diverse racial and ethnic subgroups, highlighting the potential of the assay to support more equitable care and reduce outcome disparities. The session is scheduled for PS4-09-24, Thursday, December 11, 2025, from 5:00-6:30 PM.
Real-world utilization of the 21-gene assay for guiding treatment decisions in patients with HR+/HER2- early breast cancer in the US:
Analysis demonstrates that the Oncotype DX Breast Recurrence Score test reliably guides adjuvant chemotherapy with utilization rising appropriately with higher scores and applied consistently across racial and ethnic groups, confirming equitable, guideline‑concordant treatment patterns highlighting the test’s impact in standardizing care decisions. The session is scheduled for PS2-06-21, Wednesday, December 10, 2025, from 5:00-6:30 PM.
Real-world evidence on the use of a 21-gene recurrence score assay in patients with HR+/HER2− early breast cancer in Japan: a nationwide claims database analysis:
First large-scale study of the Oncotype DX test in Japan confirmed that patients are treated at cancer-specialized or large medical centers and staging/treatment patterns show appropriate application of the Oncotype DX test in HR+/HER2 early breast cancer, consistent with current guidelines. The session is scheduled for PS3-08-28, Thursday, December 11, 2025, from 12:30-2:00 PM.
Decision-Making on Adjuvant Chemotherapy in Early HR+ Breast Cancer: A Prospective Evaluation of Oncotype DX Utility Among Swiss Breast Cancer Experts:
Study found that the Oncotype DX test significantly influenced adjuvant treatment decisions—primarily driving chemotherapy de‑escalation—and improved decision consistency among breast cancer specialists, underscoring the test’s utility in the Swiss healthcare system. The session is scheduled for PS3-10-10, Thursday, December 11, 2025, from 12:30-2:00 PM.
The Societal Cost Impact of Oncotype DX Testing in an Irish Healthcare Setting:
Use of the Oncotype DX test to identify node-positive patients that could avoid chemotherapy across 5 of Ireland’s oncology centers over an 11-year period has led to an estimated cost-savings of more than 60 million euros associated with chemotherapy use. The session is scheduled for PS3-09-03, Thursday, December 11, 2025, from 12:30-2:00 PM.
Defining postpartum breast cancer based on 21-gene recurrence score:
Breast cancer diagnosed within 5 years postpartum shows significantly higher Oncotype DX Recurrence Score results and higher histologic grade than in nulliparous peers—independent of nodal status. By stratifying risk by time since childbirth, the study refines the temporal definition of postpartum breast cancer and may inform risk stratification and treatment escalation. The session is scheduled for Poster PS3-07-11, Thursday, December 11; 2025, from 12:30-2:00 PM.
Postpartum breast cancer as a potential driver of increased 21-gene recurrence score (RS) and RS category for node-positive HR+/HER2- breast cancer:
In premenopausal, node-positive HR+/HER2− breast cancer, postpartum cases show higher Oncotype DX Recurrence Score results than nulliparous or non-postpartum cases. The study examines whether this impacts outcomes (e.g., invasive disease-free survival) to refine Recurrence Score result interpretation and better identify patients who might safely forgo chemotherapy, noting that larger studies with longer follow-up are needed. The session is scheduled for PS3-08-09, Thursday, December 11, 2025, from 12:30-2:00 PM.
Dr. Rick Baehner can be contacted for more information.
Source: Exact Sciences
